Biomarin announces new investments in Ireland

US-based biotech company Biomarin keeps investing in Ireland and expects to complete three new laboratories in Cork before Q3 2018 and to hire 50 new employees in the Cork site, which already has a workforce of 365. Biomarin reached record in sales in the last quarter and was granted approval for Brineura (Batten disease) in the US and the EU. The California-based company recently submitted to the FDA an application for pegvaliase – for the treatment of phenylketonuria – and announced promising results for BMN 270, its new hemophilia A therapy.
(Sources: Irish Times, Biomarin)